Research Article

Adipocytes from New Zealand Obese Mice Exhibit Aberrant Proinflammatory Reactivity to the Stress Signal Heat Shock Protein 60

Tina Märker,1 Jennifer Kriebel,1 Ulrike Wohlrab,1 Volker Burkart,1,2 and Christiane Habich1

1 Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, the Heinrich-Heine-University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany
2 German Center for Diabetes Research (DZD e.V.), Düsseldorf, Germany

Correspondence should be addressed to Volker Burkart; burkart@ddz.uni-duesseldorf.de

Received 25 August 2013; Revised 29 November 2013; Accepted 3 December 2013; Published 5 February 2014

Copyright © 2014 Tina Märker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adipocytes release immune mediators that contribute to diabetes-associated inflammatory processes. As the stress protein heat shock protein 60 (Hsp60) induces proinflammatory adipocyte activities, we hypothesized that adipocytes of diabetes-predisposed mice exhibit an increased proinflammatory reactivity to Hsp60. Preadipocytes and mature adipocytes from nonobese diabetic (NOD), New Zealand obese (NZO), and C57BL/6J mice were analyzed for Hsp60 binding, Hsp60-activated signaling pathways, and Hsp60-induced release of the chemokine CXCL-1 (KC), interleukin 6 (IL-6), and macrophage chemoattractant protein-1 (MCP-1). Hsp60 showed specific binding to (pre-)adipocytes of NOD, NZO, and C57BL/6J mice. Hsp60 binding involved conserved binding structure(s) and Hsp60 epitopes and was strongest to NZO mouse-derived mature adipocytes. Hsp60 exposure induced KC, IL-6, and MCP-1 release from (pre-)adipocytes of all mouse strains with a pronounced increase of IL-6 release from NZO mouse-derived adipocytes. Compared to NOD and C57BL/6J mouse derived cells, Hsp60-induced formation of IL-6, KC, and MCP-1 from NZO mouse-derived (pre-)adipocytes strongly depended on NFκB-activation. Increased Hsp60 binding and Hsp60-induced IL-6 release by mature adipocytes of NZO mice suggest that enhanced adipocyte reactivity to the stress signal Hsp60 contributes to inflammatory processes underlying diabetes associated with obesity and insulin resistance.

1. Introduction

Type 1 and type 2 diabetes account for more than 95% of all diabetes cases worldwide [1]. Although clinical characteristics show clear differences between type 1 and type 2 diabetes, recent developments indicate that the pathogenesis of the two forms of the disease share a number of fundamental features [2]. Comparative analyses particularly revealed chronic, low-grade inflammatory processes such as systemically elevated levels of proinflammatory immune mediators in both types of diabetes [3, 4]. In type 1 diabetes, systemically increased concentrations of inflammatory mediators may promote immune-mediated destruction of autologous pancreatic beta cells [5–7], whereas in type 2 diabetes, increased systemic levels of inflammatory mediators are supposed to contribute to insulin resistance, a major pathogenetic feature of the disease [8–11].

Previous studies identified the adipose tissue as a prominent source of proinflammatory cytokines and chemokines [12, 13]. This finding gains special importance in view of the observations that an increased adipose tissue mass is associated with an elevated risk for type 2 diabetes [14, 15] and an accelerated progression of type 1 diabetes [16, 17]. Further analyses identified the adipocyte population as an important cellular source of proinflammatory mediators within the adipose tissue and implicate that adipocyte-derived mediators promote local inflammatory processes as well as systemic low-grade inflammation [18–20].

Recently, we demonstrated that the (pro-)inflammatory activity of adipocytes is under control of heat shock protein...
(Hsp) 60 [21–23], a prominent member of the Hsp family [24]. The capacity to specifically bind to adipocytes and to induce the release of proinflammatory cytokines and chemokines qualifies Hsp60 as a candidate for the induction and progression of inflammatory processes associated with the development of diabetes. Initial evidence for a role of Hsp60 in the progression of insulin-deficient/type 1 diabetes came from observations in the nonobese diabetic (NOD) mouse, an animal model of type 1 diabetes which shows aberrant Hsp60 expression in pancreatic β cells already in the prediabetic phase [25]. In this model, Hsp60-directed intervention was able to attenuate diabetes [26]. Moreover, patients with type 1 diabetes have increased Hsp60 levels [27] and show delayed disease progression after treatment with the Hsp60-derived peptide p277 [28, 29]. Patients with type 2 diabetes also show elevated levels of Hsp60 in their circulation [30]. In obese individuals, Hsp60 plasma concentrations were increased and positively correlated with body mass index and insulin resistance [31].

These observations indicate that Hsp60 stimulates the proinflammatory activity of adipocytes which then might contribute to the (pro-)inflammatory processes associated with diabetes. However, the increased proinflammatory activity observed in (pre-)diabetic individuals may not only be determined by their elevated Hsp60 levels but also by an increased responsiveness of their adipocyte population to the stress protein. Currently, it is not known whether adipocytes from diabetes-prone individuals exhibit an altered Hsp60 responsiveness. We therefore hypothesized that adipocytes of diabetes-predisposed individuals exhibit an increased responsiveness to the (pro-)inflammatory effects of the stress protein Hsp60. To test the hypothesis, we compared the Hsp60 responsiveness of adipocytes from the NOD mouse, as preferred animal model of type 1 diabetes [32, 33], and from the New Zealand obese (NZO) mouse, a model of obesity and the metabolic syndrome [34]. Using adipocytes from C57BL/6J mice as reference mouse strain without diabetes risk, we investigated the decisive events assumed to be involved in Hsp60-mediated adipocyte activation: (1) the binding of Hsp60, (2) the activation of signalling pathways, and (3) the release of inflammatory mediators.

2. Materials and Methods

2.1. Animals. Normoglycemic mice (blood glucose concentration < 10 mmol/L) of the strains C57BL/6J (female), NOD (female), and NZO (male) at an age of 70 days were obtained from the breeding colonies at the German Diabetes Center. Animal experimentation was performed in accordance with the principles of laboratory animal care and was approved by the local state animal welfare committee.

2.2. Adipocyte Isolation and Culture. Preadipocytes were isolated from the visceral adipose tissue depot of the various mouse strains, cultivated, and differentiated to mature adipocytes as previously described [22]. The purity of the cell populations and their differentiation state were confirmed by lipid-specific Oil Red O staining and FACS analyses as described [21].

2.3. Antibodies and Reagents. Antibodies directed against β-actin and signalling proteins (phospho-ERK1/2 MAPK Thr202/Tyr204, phospho-p38 MAPK, phospho-SAPK/JNK Thr183/Tyr185, phospho-NFκB p65 Ser536) were purchased from Cell Signalling (Danvers, MA, USA). Murine anti-human Hsp60 Abs were from Santa Cruz (Heidelberg, Germany; clones H-1, H-300, K-19, LKI), BD Biosciences (San Diego, CA, USA; clone 24/Hsp60), Novus (Littleton, CO, USA; clone Mab11-13), Lifespan (Seattle, WA, USA; clone HSPD1), and Thermo Scientific (Rockford, IL, USA; clone 4B9/89). Isotype controls were from Cell Signalling, recombinant human Hsp60 from Loke Aps Diagnostics (Risskov, Denmark), recombinant mouse and rat Hsp60 from StressGen Biotechnologies (Victoria, BC, Canada), and recombinant hamster Hsp60 from IMMOPACT Biotechnologies GmbH (Hamburg, Germany). For inhibition studies, the specific ERK1/2 inhibitor (PD98059) and the NFκB inhibitor SN50 (Calbiochem, Darmstadt, Germany) were used.

2.4. Hsp60 Binding and Inhibition Studies. For Hsp60 binding studies, 0.5 × 10⁶ C57BL/6J, NOD, or NZO mouse-derived (pre-)adipocytes were either directly incubated with fluorescent-labelled Hsp60 (100 nM, Hsp60*) (45 min, 4°C) or preincubated with a tenfold molar excess of unlabelled Hsp60 from different species or ovalbumin (OVA, Sigma-Aldrich, Steinheim, Germany) as described [35]. For identification of Hsp60 binding epitopes, Hsp60* (100 nM) was preincubated with 0–25 μg/mL of anti-Hsp60 antibodies (45 min, 4°C) before application to (pre-)adipocytes. After washing and fixation of the cells in 2% paraformaldehyde, Hsp60* binding was calculated from the geometric mean fluorescence after subtracting the autofluorescence as determined by analyses in a FACS Calibur flow cytometer (BD Biosciences).

2.5. Release of Inflammatory Mediators. C57BL/6J, NOD, and NZO mouse-derived (pre-)adipocytes were exposed to medium or 1–20 μg/mL recombinant human Hsp60 (ENZO Life Sciences, Lörrach, Germany). After 24 h, the concentrations of the inflammatory mediators interleukin-6 (IL-6), mouse chemokine CXCL-1 (KC), and monocyte chemoattractant protein-1 (MCP-1) were determined in the culture supernatants by multiplex-beads-systems (Luminex Corp., Austin, TX, USA).

2.6. Analyses of Signaling Pathways. To identify Hsp60-activated signaling pathways, C57BL/6J, NOD, and NZO mouse-derived (pre-)adipocytes were seeded in 6 cm petri dishes (2 × 10⁶ cells/5 mL medium). Cells were treated with medium or Hsp60 (10 μg/mL) (15 min, 37°C) and subsequently washed and treated with lysis-buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.25% Na-Desoxycholate) including protease and phosphatase inhibitors (Roche, Mannheim, Germany) (20 min, 4°C). After centrifugation
(15 min, 10,000 ×g, 4°C) cell lysates were subjected to SDS-PAGE (10%) and appropriate antibodies for detection of activated signal proteins were applied for immunoblot analysis. Signals were visualized by the Lumi-Imager system (Roche Applied Science, Mannheim, Germany). To analyse the effect of specific signal protein inhibitors on the Hsp60-mediated secretion of inflammatory mediators, 1 × 10⁵ C57BL/6J, NOD, and NZO mouse-derived (pre-)adipocytes were seeded in 1 mL per well of a 48 well plate and incubated (1h, 37°C) either with medium (control), ERK1/2 inhibitor PD98059 (100 μg/mL), or NFκB inhibitor SN50 (50 μg/mL). Afterwards, cells remained unstimulated (medium) or were stimulated with Hsp60 (10 μg/mL) for 24 h. Supernatants were collected to determine the concentrations of IL-6, KC, and MCP-1 by multiplex-beads-assays.

2.7. Statistical Analysis. Data were expressed as means ± SEM. Statistical analysis was performed using the Student’s t-test. Differences were considered statistically significant with P < 0.05.

3. Results

3.1. Hsp60 Binds Specific to C57BL/6J, NOD, and NZO Mouse-Derived Primary (Pre-)Adipocytes. To characterize the interaction between Hsp60 and primary (pre-)adipocytes from C57BL/6J, NOD, and NZO mice, we investigated the binding of fluorescent-labeled Hsp60 (Hsp60*, 100 nM) to preadipocytes and in vitro differentiated, mature adipocytes of the three mouse strains. FACS analyses demonstrated substantial binding of Hsp60 to adipocyte populations of all mouse strains (Figures 1(a)–1(f)). Comparison of the mean fluorescence signals revealed Hsp60 binding intensities of preadipocytes from C57BL/6J, NOD, and NZO mice within a range of geo means from 19 to 30 (Figure 1(g)). Among the adipocyte populations, NZO mouse-derived adipocytes revealed maximum Hsp60 binding (geo mean 38.0 ± 10.7)

The specificity of Hsp60-(pre-)adipocyte interaction was proven by inhibition of Hsp60* binding to cells preincubated with excess unlabelled Hsp60 (1000 nM) to 23.1 ± 2.7% (C57BL/6J), 20.4 ± 1.9% (NOD), and 28.7 ± 2.5% (NZO) (P < 0.05) (Figure 1(h)). Preincubation of the cells with OVA did not significantly affect Hsp60 binding. The extent of inhibition of Hsp60 binding to mature adipocytes was only marginally lower than that observed for preadipocytes.

3.2. Characterization of the Interaction of Different Hsp60 Species with C57BL/6J, NOD, and NZO Mouse-Derived (Pre-)Adipocytes. Based on our previous observation that different eukaryotic Hsp60 species recognize the same receptor structure(s) on cells of the murine adipocyte line 3T3-L1 [35], we investigated the effect of eukaryotic (human, mouse, rat, and hamster) and prokaryotic Hsp60 species (E. coli, M. bovis) on the binding of human Hsp60 to primary C57BL/6J, NOD, and NZO mouse-derived (pre-)adipocytes. Strong inhibition of Hsp60* binding to preadipocytes was observed after preincubation of Hsp60* with the mammalian Hsp60 species (Figure 2). Preincubation with human Hsp60 induced maximum inhibitory effects by reducing Hsp60* binding to preadipocytes from the three mouse strains to 28.9 ± 14.5% (C57BL/6J), 33.9 ± 18.4% (NOD), and 34.1 ± 17.4% (NZO). Except for GroEL-mediated inhibition of Hsp60* binding to C57BL/6J mouse-derived preadipocytes, preincubation with prokaryotic Hsp60 species did not significantly affect Hsp60* binding to preadipocyte populations (Figure 2). For primary, in vitro differentiated adipocytes comparable results were obtained (data not shown).

3.3. Characterization of Hsp60 Binding Epitope(s) Involved in the Interaction with C57BL/6J, NOD, and NZO Mouse-Derived (Pre-)Adipocytes. Our further experiments focused on the identification of the Hsp60 epitope(s) potentially involved in the interaction of the stress protein with (pre-)adipocytes. In an initial approach, we investigated the effect of antibodies against distinct regions of the Hsp60 molecule, on the binding of Hsp60 to C57BL/6J, and NOD mouse-derived preadipocytes. FACS analyses revealed largely comparable patterns of antibody-mediated inhibition of Hsp60 binding to preadipocyte populations of both mouse strains (Table I). Preincubation of the cells with antibodies against the N-terminal (aa50–200 (clone H1), aal-200 (clone 24/HSP60)), and C-terminal (aa523-573 (clone K19)) regions of the Hsp60 molecule resulted in strongest reduction of Hsp60 binding to 25.5 ± 0.6%.

Subsequently, we preincubated fluorescent-labeled Hsp60 with increasing concentrations (0–25 μg/mL) of the antibodies initially found to inhibit Hsp60 binding (clones H1, 24/HSP60, K-19 (Table I)) prior addition to (pre-)adipocytes from C57BL/6J, NOD, or NZO mice (Figure 3). In C57BL/6J mouse-derived preadipocytes, Hsp60 binding was reduced dose-dependently to 51.2 ± 9.1% by the application of the antibody clone H-1 (aa50–200, 25 μg/mL) and to 28.0 ± 2.6% by applying antibody clone 24/HSP60 (aa1-200, 25 μg/mL). In contrast, clone K-19 (aa523-573) did not induce clear dose-dependent inhibition of Hsp60 binding. Comparable inhibitory effects were obtained for preadipocytes from NOD and NZO mice. Clone H-1 (aa50–200) reduced Hsp60 binding to 38.2 ± 12.5% (NOD) and to 47.0 ± 2.9% (NZO); clone 24/HSP60 (aa1-200) reduced Hsp60 binding to 23.3 ± 4.9% and to 18.6 ± 3.5% in NOD and NZO mouse-derived cells, respectively. As in C57BL/6J preadipocytes, no clear dose-dependent effects were observed for NOD and NZO mouse-derived preadipocytes preincubated with the antibody against the C-terminal region of Hsp60 (clone K-19, aa523-573). In binding studies with mature adipocytes, the antibodies yielded similar inhibition patterns (data not shown).

3.4. Hsp60-Induced Release of Inflammatory Mediators by C57BL/6J, NOD, and NZO Mouse-Derived Adipocyte Populations. To compare adipocyte populations from different mouse models of diabetes for their ability to release inflammatory mediators, we investigated the accumulation of KC, IL-6, and MCP-1 in cultures of (pre-)adipocytes derived from C57BL/6J, NOD, and NZO mice (Figure 4). Unstimulated cells of the three mouse strains spontaneously accumulated...
Figure 1: Hsp60 binding to C57BL/6J, NOD, and NZO mouse-derived (pre-)adipocytes. Preadipocytes (a, c, e) or adipocytes (b, d, f) of the three mouse strains were incubated with 100 nM DyLight649-labeled Hsp60 (Hsp60*) in the absence or presence of 1 \( \mu \)M unlabeled Hsp60 or OVA. Binding of Hsp60* was quantified by determining the mean fluorescence intensities (geo mean) of the cell populations using FACS analysis. The data show representative results of Hsp60* binding and inhibition studies (a–f) and of Hsp60* binding to C57BL/6J (light grey bars), NOD (dark grey bars), and NZO mouse-derived cells (black bars) as means + SEM of three independent experiments (g). The specificity of Hsp60* binding was proven by analyses of the effects of unlabelled Hsp60 or OVA (h). The data represent residual Hsp60* binding to C57BL/6J (light grey bars), NOD (dark grey bars), and NZO mouse-derived cells (black bars) as percent of Hsp60* binding (set as 100%, white bar) in the absence of Hsp60 or OVA. The data show means + SEM of three independent experiments. * \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \) compared to other mouse strains (g) or compared to Hsp60* binding in the absence of Hsp60 or OVA (h).
substantial amounts of most of the mediators in their supernatants (Figures 4(a) and 4(b)). Independent of the mouse strain, preadipocyte and adipocyte populations released KC in a concentration range of 4.3–12.9 ng/mL and MCP-1 in a range of 13.3–271 ng/mL. The amounts of IL-6 released from C57BL/6J and NOD mouse-derived (pre-)adipocytes were in a range of 0.7–9.8 ng/mL, whereas (pre-)adipocytes from NZO mice released exceptionally low levels of the cytokine (0.7 ± 0.3 ng/mL and 0.9 ± 0.3 ng/mL IL-6, resp.) \( P < 0.05 \).

Exposure of the (pre-)adipocyte populations to rising Hsp60 concentrations (1–20 μg/mL) for 24 h caused a dose-dependent increase of the secretion of KC, IL-6, and MCP-1 in a cell type- and mouse strain-specific manner (Figures 4(c)–4(h)). However, whereas the cytokine release from NOD mouse-derived cell populations largely resembled the pattern of C57BL/6J mouse-derived cells, adipocyte populations from NZO mice showed an enhanced release of KC and IL-6. In particular, a strong, 3.9 ± 0.2-fold increase of KC release from NZO mouse-derived adipocytes was observed when compared to adipocytes from C57BL/6J (1.7 ± 0.2-fold increase, \( P < 0.05 \)) and from NOD mice (2.4 ± 0.7-fold increase) (Figure 4(d)). Moreover, the release of IL-6 induced by Hsp60 (20 μg/mL) was strikingly increased from NZO mouse-derived preadipocytes (7.7 ± 1.0-fold) and adipocytes (19.1 ± 4.0-fold) when compared to the corresponding cell populations of C57BL/6J and NOD mice (\( P < 0.05 \)) (Figures 4(e) and 4(f)).

3.5. Characterization of Hsp60-Activated Signaling Pathways in C57BL/6J, NOD, and NZO Mouse-Derived (Pre-)Adipocytes

We further investigated the effect of Hsp60 on the stimulation of proinflammatory signaling pathways by analyzing the activation (phosphorylation) of members of the MAP kinase family (ERK1/2, JNK(p46), p38) and of the transcription factor NFκB in (pre-)adipocytes of C57BL/6J, NOD, and NZO mice (Figure 5). Hsp60 treatment did not activate ERK1/2, JNK(p46), and p38 in preadipocytes of the three mouse strains (Figure 5(a)). On the other hand, NFκB activation was increased to a similar degree in NOD and NZO mouse-derived preadipocytes (2.6±0.2-fold and 2.6±0.5-fold, resp.) \( P < 0.05 \) but not in C57BL/6J mouse-derived cells. In contrast to the Hsp60 effects observed in preadipocytes, Hsp60 exposure of mature adipocytes increased the activation of ERK1/2 (2.1 ± 0.2-fold, \( P < 0.01 \)) and NFκB (3.5 ± 0.2-fold, \( P < 0.01 \) in C57BL/6J mouse-derived cells, whereas in cells from the diabetes predisposed mouse strains, Hsp60-induced activation of the investigated pathways was only moderate or low (<2-fold) (Figure 5(b)). These results show that Hsp60 preferentially controls ERK1/2- and NFκB-dependent pathways in a differential manner depending on the maturation state of the adipocytes and on the donor mouse strain. We therefore focused our further analyses on the involvement of ERK1/2 and NFκB in Hsp60-induced
cytokine release by the use of specific inhibitors of the signaling molecules.

Exposure of adipocytes of C57BL/6J and NOD mice to the ERK1/2-inhibitor PD98059 reduced the Hsp60-induced release of IL-6, KC, and MCP-1 to 16 to 67% (P < 0.05) of the levels detectable in cultures treated with Hsp60 alone (Figures 6(a), 6(c), and 6(e)). However, in NZO mouse-derived adipocytes, the Hsp60-induced cytokine pattern showed a differential response to ERK1/2 inhibition, whereas in the presence of PD98059, the formation of IL-6 remained largely unaffected (relative IL-6 secretion 89.7 ± 10.9%) (Figure 6(a)), the residual KC formation was in the range of the levels detected in C57BL/6J and NOD mouse derived cells (48.7 ± 3.8%, P < 0.001) (Figure 6(c)) and the release of MCP-1 was strongly reduced to 28.7 ± 9.1% (P < 0.001) (Figure 6(e)). Inhibition of NFκB by SN50 resulted in the reduction of cytokine release in a similar range in cultures of (pre-)adipocytes from C57BL/6J and NOD mouse (29–70%) (P < 0.01) (Figures 6(b), 6(d), and 6(f)). The strongest inhibition of Hsp60-induced IL-6, KC, and MCP-1 release was found in SN50-exposed (pre-)adipocytes from NZO mice. In NZO mouse-derived preadipocytes, the NFκB inhibitor significantly reduced IL-6 release to 3.0 ± 2.1%, KC release to 15.0 ± 4.7%, and MCP-1 release to 5.1 ± 3.6% (P < 0.001) of the cytokine levels measured in the absence of the inhibitor. In adipocytes, NFκB inhibition reduced IL-6 release to less than 0.1%, KC release to 19.7 ± 9.8%, and MCP-1 release to 26.3 ± 9.1% (P < 0.001).

4. Discussion

Previous observations suggest an essential contribution of obesity-associated inflammatory processes to the development of type 2 diabetes [10, 11] as well as type 1 diabetes [5]. Further studies, based on the finding of the strong immunomodulatory capacity of adipocytes, identified the stress protein Hsp60 as a potent inducer of proinflammatory mediators from murine and human adipocytes [21, 31]. These findings implicate that Hsp60-induced adipocyte mediators promote the development of obesity- and diabetes-associated inflammatory processes and further raise the question whether adipocytes from diabetes-prone subjects exhibit an aberrant reactivity to the stress protein.

To address this issue, we examined the effect of Hsp60 on adipocyte populations derived from the currently best characterized animal models of the two prevailing forms of human diabetes. Diabetes observed in the NOD mouse reflects major features of human type 1 diabetes [32, 33], whereas the metabolic abnormalities developing in the NZO mouse largely resemble the dysregulations of energy metabolism and glucose homeostasis associated with human type 2 diabetes [34]. As reference, adipocytes from the metabolically healthy mouse strain C57BL/6J were used. For our studies, we selected adipocyte populations isolated from the visceral fat depot as adipose tissue from this anatomical location had been identified as a major source of mediators responsible for diabetes-associated metabolic and immunologic disorders [36, 37]. As previous reports indicate that the functional properties of adipocytes depend on their maturation state [38, 39], we investigated Hsp60 effects on preadipocytes as well as terminally differentiated adipocytes.

Our approach focused on the decisive steps assumed to be involved in Hsp60-mediated inflammatory adipocyte activation: (1) the binding of Hsp60 to adipocytes regarded as the primary event in Hsp60-adipocyte interaction, (2) the activation of intracellular signaling pathways, and (3) the resulting release of inflammatory mediators which may act as signaling molecules in an autocrine manner and/or in the attraction and stimulation of immune cells.

Initial comparative FACS studies with fluorescent-labeled Hsp60 revealed that preadipocytes and mature adipocytes of all investigated mouse strains are able to bind Hsp60. Binding of the stress protein was highly specific as demonstrated by
Figure 4: Hsp60-induced release of inflammatory mediators by (pre-)adipocytes from C57BL/6J, NOD, and NZO mice. (Pre-)adipocytes from C57BL/6J (light grey bars) NOD (dark grey bars), and NZO mice (black bars), were incubated in the absence (a, b) or presence (c–h) of increasing concentrations of Hsp60 (1–20 μg/mL) and the accumulation of KC, IL-6, and MCP-1 in the culture supernatants was analyzed by multiplex-beads-assay after 24 h. The results show concentrations of accumulated cytokines (a, b) or of cytokine release relative to the cytokine levels detected in the supernatants of unstimulated cells (c–h). The data represent means ± SEM of three independent experiments, each performed in triplicates. *P < 0.05, **P < 0.01, ***P < 0.001 compared to other mouse strains.
efficient inhibition after preincubation of the cells with unlabelled Hsp60. Interestingly, the observed characteristics of Hsp60-(pre-)adipocyte interaction showed striking similarities with Hsp60 binding by macrophages which was investigated in more detail in previous studies [40, 41]. These analyses demonstrated specific, receptor-mediated Hsp60 binding to the cell surface. Further studies revealed that the receptor structure for Hsp60 acts in a stereospecific manner, includes at least two functionally different components engaged in binding and signal transduction, differs from receptors for other heat shock proteins, and triggers endocytosis of its bound ligand. Considering the observed similarities in Hsp60 binding to (pre-)adipocytes and macrophages and in view of the close relationship between cells of the adipocyte and macrophage lineages [42], it may be concluded that Hsp60 binding to adipocytes is mediated by similar receptor-mediated mechanisms as the above mentioned mechanisms described for macrophages.

Interestingly, although efficient Hsp60 binding to adipocytes of all three mouse strains was observed, we found strongly enhanced binding of the stress protein to mature NZO mouse-derived adipocytes when compared to cells from C57BL/6J (and NOD) mice of the same maturation state. This finding may be of special importance in view of the fact that NZO mice are characterized by an increased body fat mass which most likely includes a large proportion of terminally differentiated adipocytes [43].

In more detailed studies, we attempted to identify Hsp60 epitopes involved in the interaction of the stress protein with (pre-)adipocytes. Competition experiments with various Hsp60 species and with inhibitory antibodies directed against defined Hsp60 epitopes revealed that eukaryotic Hsp60 molecules bind to (pre-)adipocytes via highly conserved aminoacid sequences within the N-terminal region.

Collectively, our studies on Hsp60-(pre-)adipocyte interaction demonstrate efficient Hsp60-binding to primary NOD mouse-derived adipocytes, thereby extending our previous observations of specific Hsp60 interaction with adipocytes from NZO mice and with cells of the murine adipocyte line 3T3-L1 [22]. Hence, our findings provide further evidence for the assumption that the ability to bind Hsp60 represents a general property of murine adipocytes irrespective of their origin and differentiation state. Nevertheless, further extensive biochemical studies will be necessary to gain further insight into the structural and functional properties of the Hsp60 receptor structure on (pre-)adipocytes.

Previous studies identified stress proteins as potent inducers of intracellular signaling pathways. We therefore investigated the effects of Hsp60 on the activation of the MAP kinases ERK1/2, JNK, and p38 and of the transcription factor NFκB which are preferentially activated by stress signals but are also essential for the coordination of adipocyte differentiation [44–46]. Due to the marked interdependence of signaling and differentiation pathways, we hypothesized that the response of the adipocyte populations depends on the maturation state of the cells. In fact, Hsp60 exposure induced increased ERK1/2 activation in (mature) adipocytes from normal control C57BL/6J mice and enhanced activation of ERK1/2 and p38 in adipocytes from NOD mice. In contrast, Hsp60-exposed preadipocytes did not reveal consistent activation of MAP kinases. With regard to NFκB, we found an elevated activation of the transcription factor in preadipocytes from diabetes-prone NOD and NZO mice but reduced activation in mature adipocytes of the two mouse strains, when compared to the reactivity of cell populations from normal control C57BL/6J mice. As NFκB represents an important transcriptional regulator of inflammatory mediators [47], our findings implicate that preadipocytes of NOD...
Collectively, our findings implicate that the Hsp60-induced activation of intracellular signaling pathways in adipocytes not only depends on the differentiation state of the cells but also on the donor mouse strain. Our observations particularly suggest that aberrant intracellular signaling and disturbed transcriptional regulation in adipocytes enhance diabetes-promoting inflammatory reactivity in animals with a genetic predisposition to develop diabetes. In fact, previous studies demonstrated aberrant activation of MAP kinases, including p38, [48, 49] and a dysregulation of transcription factors, including NFκB [50–52] in diabetes-prone mouse strains. Although these findings are mainly derived from macrophages, they obviously reflect intrinsic disturbances of signaling and transcriptional processes in diabetes prone NOD and NZO mice that may contribute to the aberrant activation of MAP kinases and NFκB observed in Hsp60-exposed (pre-)adipocytes of these animals. Further studies on the elucidation of the intracellular signaling cascade triggered by stress signals (will) have to consider the complex situation that most components of the stress response pathways are also critical for the control of adipocyte differentiation [45, 50–52].

The release of proinflammatory adipocyte mediators induced by Hsp60 and the intracellular signaling pathways
engaged in this process were further analyzed by focusing on the formation of KC, IL-6, and MCP-1 which had been identified as prominent factors released by adipocytes and are supposed to contribute to obesity-associated inflammatory processes [53–55]. Unstimulated preadipocytes and adipocytes of C57BL/6J, NOD, and NZO mice released substantial amounts of these mediators, with the exception of NZO mouse-derived adipocyte populations which released markedly low amounts of IL-6. Hsp60, applied at concentrations that largely correspond to the levels found in individuals suffering from cardiovascular and arthritic disorders [56, 57], dose-dependently increased the release of KC, IL-6, and MCP-1 by preadipocytes and adipocytes from the three mouse strains. These results extend our initial observations on the pronounced Hsp60 responsiveness of adipocytes of mouse strains. These results extend our initial observations and MCP-1 by preadipocytes and adipocytes from the three mouse strains. These results extend our initial observations from the two diabetes-predisposed mouse strains largely resembled the pattern of cells derived adipocyte populations from cells from C57BL/6J and NOD mice.

The potential impact of the donor mouse strain on MAP kinase-dependent signaling and transcriptional regulation in the Hsp60-induced formation of inflammatory adipocyte mediators was further elucidated by selective inhibition of the signaling molecules. Blocking of signaling pathways by specific inhibitors [58, 59] confirmed the involvement of ERK1/2 and NFκB in the Hsp60-induced release of adipocyte mediators. Unexpectedly, the experiments revealed strong differences between the reactivities of adipocyte populations from the two diabetes-predisposed mouse strains. After ERK1/2 or NFκB inhibition, the reactivity pattern of NOD mouse-derived cells largely resembled the pattern of cells from normal control C57BL/6J mice. However, in adipocyte populations of NZO mice, ERK1/2 dependency was low for IL-6 production, intermediate for KC production, and high for MCP-1 production when compared to C57BL/6J and NOD mouse-derived cells. Moreover, NFκB suppression caused strongest inhibition of 75–98% in cultures of NZO mouse-derived cells pointing to a dominant role of NFκB in the formation of proinflammatory mediators from Hsp60-exposed adipocytes in this mouse strain. This finding appears to be in discrepancy with our above-mentioned results demonstrating that NOD and NZO mouse-derived adipocytes show largely comparable activation levels of MAP kinases and NFκB after Hsp60 exposure. These contrasting observations obviously reflect strain-specific differences in the preferential usage of intracellular pathways of signaling and transcriptional regulation (other than NFκB-dependent) to induce the formation of inflammatory mediators in response to Hsp60. This assumption is supported by the finding of aberrant activation of intracellular signaling pathways in diabetes-prone mouse strains [49, 51, 52]. Furthermore, the promoter regions of many genes encoding inflammatory mediators (e.g., IL-6, MCP-1) also have binding sites for other transcription factors including activator protein 1 and members of the CCAAT-enhancer binding protein family [60–62]. It might be speculated that these factors could be used alternatively to NFκB in the induction of proinflammatory adipocyte mediators in different mouse strains, depending, for example, on their genetic predisposition to develop a specific form of diabetes.

Taken together, our observations in C57BL/6J, NOD, and NZO mouse-derived adipocyte populations indicate that the basic structural requirements, such as receptor structure(s) and Hsp60 binding epitopes, involved in the initial recognition of the stress protein, share a high degree of similarity, and irrespective of the donor and of the differentiation state of the cells. However, clear differences between the mouse strains were found regarding the efficiency of Hsp60 binding, the patterns of intracellular signaling pathways activated by Hsp60, and the resulting release of inflammatory mediators. These findings warrant further extensive studies for the detailed elucidation of mouse strain dependency and the roles of intracellular signaling pathways in Hsp60-induced adipocyte stimulation.

NOD mice typically exhibit a lean constitution and, accordingly, a low number of (mature) adipocytes. Moreover, the Hsp60 responsiveness of NOD mouse-derived adipocytes largely corresponds to the reactivity of adipocytes of normal healthy C57BL/6J mice. Based on these considerations, it may be concluded that in NOD mice, Hsp60-induced proinflammatory adipocyte activities do not play a decisive role in the progression of (insulin deficient) diabetes. In NZO mice, however, improved Hsp60 binding and dysregulation of IL-6 formation reflect an increased proinflammatory reactivity, preferably of mature adipocytes. In addition, the pathological increase of the adipose tissue mass by adipocyte-hyperplasia and proliferation inevitably leads to an elevated number of (mature) adipocytes in these mice. As a result, the enhanced release of chemotactic and stimulatory adipocyte mediators may contribute not only to the acceleration of immune cell infiltration into the adipose tissue but also to an elevation of systemic inflammatory mediators which may aggravate peripheral insulin resistance, thereby promoting the progression of metabolic dysregulation and diabetes. Moreover, during the development of obesity, the expanding adipose tissue itself may create an increasingly stressful environment in which infiltrating immune cells (e.g., macrophages) and adipocytes themselves may become relevant sources of Hsp60 and other stress signals.

**Abbreviations**

CXCL-1/KC: Chemokine (C-X-C motif) ligand 1  
ERK1/2: Extracellular signal-regulated kinase 1/2  
Hsp(60): Heat shock protein (60)  
JNK: c-Jun N-terminal kinase  
MCP-1: Macrophage chemoattractant protein 1  
MAPK: Mitogen-activated protein kinase  
NFκB: Nuclear transcription factor κB  
NZO: New Zealand obese  
OVA: Ovalbumin  
PBMC: Peripheral blood mononuclear cells  
PBS: Phosphate buffered saline.
Conflict of Interests

The authors declare that there is no conflict of interests associated with this paper.

Authors’ Contribution

Tina Märker contributed to the design of the paper, performed experiments, and analyzed and interpreted the data; Jennifer Kriebel and Ulrike Wohlrab performed experiments and analyzed and interpreted the data; Volker Burkart contributed to the conception of the paper, interpretation of data, and revising the paper; and Christiane Habich coordinated research, contributed to the conception and design of the experiments, and drafted the paper. All authors approved the final version of the paper.

Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft, the Deutsche Diabetes-Gesellschaft, the Bundesminister für Gesundheit, the Minister für Innovation, Forschung und Technologie des Landes Nordrhein-Westfalen, and in part by a grant from the Bundesministerium für Bildung und Forschung to the German Center for Diabetes Research (Deutsches Zentrum für Diabetes-Forschung (DZD e.V.).

References

[1] “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010.
[2] T. Tuomi, “Type 1 and type 2 diabetes: what do they have in common?” Diabetes, vol. 54, supplement 2, pp. S40–S45, 2005.
[3] K. I. Alexandraki, C. Piperi, P. D. Ziakas et al., “Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation,” The Journal of Clinical Immunology, vol. 28, no. 4, pp. 314–321, 2008.
[4] R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 9, pp. S171–S182, 2009.
[5] J. K. Snell-Bergeon, N. A. West, E. J. Mayer-Davis et al., “Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 6, pp. 2868–2876, 2010.
[6] A. Schölén, A. Siegbahn, L. Lind et al., “CRP and IL-6 concentrations are associated with poor glycemic control despite preserved β-cell function during the first year after diagnosis of type 1 diabetes,” Diabetes Metabolism Research and Reviews, vol. 20, no. 3, pp. 205–210, 2004.
[7] S. Devaraj, A. T. Cheung, I. Jialal et al., “Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications,” Diabetes, vol. 56, no. 11, pp. 2790–2796, 2007.
[8] C. Herder, J. Baumert, B. Thorand et al., “Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002,” Diabetologia, vol. 49, no. 5, pp. 921–929, 2006.
[9] A. Pradhana, “Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders,” Nutrition Reviews, vol. 65, no. 12, part 2, pp. S152–S156, 2007.
[10] H. Kolb and T. Mandrup-Poulsen, “The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation,” Diabetologia, vol. 53, no. 1, pp. 10–20, 2010.
[11] C. J. Shu, C. Benoist, and D. Mathis, “The immune system’s involvement in obesity-driven type 2 diabetes,” Seminars in Immunology, vol. 24, no. 6, pp. 436–442, 2012.
[12] K. E. Wellen and G. S. Hotamisligil, “Obesity-induced inflammatory changes in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1785–1788, 2003.
[13] L. Fontana, J. C. Eagon, M. E. Trujillo, P. E. Scherer, and S. Klein, “Visceral fat adipokine secretion is associated with systemic inflammation in obese humans,” Diabetes, vol. 56, no. 4, pp. 1010–1013, 2007.
[14] J. M. Chan, E. B. Rimm, G. A. Colditz, M. J. Stampfer, and W. C. Willett, “Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men,” Diabetes Care, vol. 17, no. 9, pp. 961–969, 1994.
[15] G. A. Colditz, W. C. Willett, A. Rotnitzky, and J. E. Manson, “Weight gain as a risk factor for clinical diabetes mellitus in women,” Annals of Internal Medicine, vol. 122, no. 7, pp. 481–486, 1995.
[16] T. J. Wilkin, “The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes,” Diabetologia, vol. 44, no. 7, pp. 914–922, 2001.
[17] P. Betts, J. Mulligan, P. Ward, B. Smith, and T. Wilkin, “Increasing body weight predicts the earlier onset of insulin-dependent diabetes in childhood: testing the “accelerator hypothesis” (2),” Diabetic Medicine, vol. 22, no. 2, pp. 144–151, 2005.
[18] T. Christiansen, B. Richelsen, and J. M. Bruun, “Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects,” International Journal of Obesity, vol. 29, no. 1, pp. 146–150, 2005.
[19] Y. Fu, L. Luo, N. Luo, and W. T. Garvey, “Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes,” Nutrition & Metabolism, vol. 3, article 28, 2006.
[20] A. Schäffler, U. Müller-Ladner, J. Schölmerich, and C. Büchner, “Role of adipose tissue as an inflammatory organ in human diseases,” Endocrine Reviews, vol. 27, no. 5, pp. 449–467, 2006.
[21] E. Gündüz, S. Mollèrus, J. Brüggemann, V. Burkart, and C. Habich, “Heat shock protein 60 induces inflammatory mediators in mouse adipocytes,” FEBS Letters, vol. 582, no. 18, pp. 2731–2736, 2008.
[22] E. Gündüz, T. Märker, J. Kriebel, V. Kolb-Bachofen, V. Burkart, and C. Habich, “Heat shock protein 60: evidence for receptor-mediated induction of proinflammatory mediators during adipocyte differentiation,” FEBS Letters, vol. 583, no. 17, pp. 2877–2881, 2009.
[23] T. Märker, J. Kriebel, U. Wohlrab, and C. Habich, “Heat shock protein 60 and adipocytes: characterization of a ligand-receptor interaction,” Biochemical and Biophysical Research Communications, vol. 391, no. 4, pp. 1634–1640, 2010.
[24] A. L. Fink, “Chaperone-mediated protein folding,” Physiological Reviews, vol. 79, no. 2, pp. 425–449, 1999.
[25] K. Brudzynski, “Insulitis-caused redistribution of heat-shock protein HSP60 inside β-cells correlates with induction of HSP60 autoantibodies,” *Diabetes*, vol. 42, no. 6, pp. 908–913, 1993.

[26] Y. J. Ma, Y. Lu, J. Hou et al., “Vaccination of non-obese diabetic mice with a fragment of peptide P277 attenuates insulin-dependent diabetes mellitus,” *International Immunopharmacology*, vol. 11, no. 9, pp. 1298–1302, 2011.

[27] S. Devaraj, M. R. Dasu, S. H. Park, and I. Jialal, “Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes,” *Diabetologia*, vol. 52, no. 8, pp. 1665–1668, 2009.

[28] I. Raz, D. Elias, A. Avron, M. Tamir, M. Metzger, and I. R. Cohen, “β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (Dia-Pep277): a randomised, double-blind, phase II trial,” *The Lancet*, vol. 358, no. 9295, pp. 1749–1753, 2001.

[29] V. A. L. Huurman, P. E. Van Der Meide, G. Duinkerken et al., “Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type 1 diabetes,” *Clinical & Experimental Immunology*, vol. 152, no. 3, pp. 488–497, 2008.

[30] M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, “Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects,” *Diabetes Care*, vol. 33, no. 4, pp. 861–868, 2010.

[31] T. Märker, H. Sell, P. Zillesen et al., “Heat shock protein 60 as a mediator of adipose tissue inflammation and insulin resistance,” *Diabetes*, vol. 61, no. 3, pp. 615–625, 2012.

[32] R. J. Chaparro and T. P. Dilorenzo, “An update on the use of NOD mice to study autoimmune (Type 1) diabetes,” *Expert Review of Clinical Immunology*, vol. 6, no. 6, pp. 939–955, 2010.

[33] F.-C. Chou, H.-Y. Chen, S.-J. Chen, M.-C. Fang, and H.-K. Sytwu, “Rodent models for investigating the dysregulation of immune responses in type 1 diabetes,” *Journal of Diabetes Research*, vol. 2013, Article ID 138412, 8 pages, 2013.

[34] H.-G. Joost, “The genetic basis of obesity and type 2 diabetes: lessons from the New Zealand obese mouse, a polygenic model of the metabolic syndrome,” *Results and Problems in Cell Differentiation*, vol. 52, pp. 1–11, 2010.

[35] C. Habich, K. Kempe, R. Van Der Zee, V. Burkart, and H. Kolb, “Different heat shock protein 60 species share pro-inflammatory activity but not binding sites on macrophages,” *FEBS Letters*, vol. 553, no. 1–3, pp. 105–109, 2003.

[36] I. Gabriely, X. H. Ma, X. M. Yang et al., “Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?” *Diabetes*, vol. 51, no. 10, pp. 2951–2958, 2002.

[37] S. K. Fried, D. A. Bunkin, and A. S. Greenberg, “Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 83, no. 3, pp. 847–850, 1998.

[38] T. Wada, S. Shimba, and M. Tczuka, “Transcriptional regulation of the hypoxia inducible factor-2α (HIF-2α) gene during adipose differentiation in 3T3-L1 cells,” *Biological & Pharmaceutical Bulletin*, vol. 29, no. 1, pp. 49–54, 2006.

[39] J. M. Harkins, N. Moustaid-Moussa, Y.-J. Chung et al., “Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice,” *Journal of Nutrition*, vol. 134, no. 10, pp. 2673–2677, 2004.

[40] C. Habich, K. Baumgart, H. Kolb, and V. Burkart, “The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins,” *The Journal of Immunology*, vol. 168, no. 2, pp. 569–576, 2002.

[41] C. Habich and V. Burkart, “Heat shock protein 60: regulatory role on innate immune cells,” *Cellular and Molecular Life Sciences*, vol. 64, no. 6, pp. 742–751, 2007.

[42] G. Charrière, B. Cousin, E. Arnaud et al., “Preadipocyte conversion to macrophage: evidence of plasticity,” *The Journal of Biological Chemistry*, vol. 278, no. 11, pp. 9850–9855, 2003.

[43] L. Herberg and D. L. Coleman, “Laboratory animals exhibiting obesity and diabetes syndromes,” *Metabolism*, vol. 26, no. 1, pp. 59–99, 1977.

[44] M. Rincón and R. J. Davis, “Regulation of the immuneresponse by stress-activated protein kinases,” *Immunological Reviews*, vol. 228, no. 1, pp. 212–224, 2009.

[45] R. G. Baker, M. S. Hayden, and S. Ghosh, “NF-κB, inflammation, and metabolic disease,” *Cell Metabolism*, vol. 13, no. 1, pp. 11–22, 2011.

[46] F. Bost, M. Aouadi, L. Caron, and B. Binetruy, “The role of MAPKs in adipocyte differentiation and obesity,” *Biochimie*, vol. 87, no. 1, pp. 51–56, 2005.

[47] B. Hoesel and J. A. Schmid, “The complexity of NF-κB signaling in inflammation and cancer,” *Molecular Cancer*, vol. 12, article 86, 2013.

[48] J. Zhang, N. Zhu, Q. Wang et al., “MEKK3 overexpression contributes to the hyperresponsiveness of IL-12–overproducing cells and CD4+ T conventional cells in nonobese diabetic mice,” *The Journal of Immunology*, vol. 185, no. 6, pp. 3554–3563, 2010.

[49] J. Zhang, K. V. Salojin, and T. L. Delovitch, “CD28 co-stimulation restores T cell responsiveness in NOG mice by overcoming deficiencies in Rac-1/p38 mitogen-activated protein kinase signaling and IL-2 and IL-4 gene transcription,” *International Immunology*, vol. 13, no. 3, pp. 377–384, 2001.

[50] J. Liu and D. Beller, “Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-κB expression and binding to the IL-12 p40 promoter,” *The Journal of Immunology*, vol. 169, no. 1, pp. 581–586, 2002.

[51] J. Liu and D. I. Beller, “Distinct pathways for NF-κB regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains,” *The Journal of Immunology*, vol. 170, no. 9, pp. 4489–4496, 2003.

[52] W. Becker, R. Kluge, T. Kantner et al., “Differential hepatic gene expression in a polygenic mouse model with insulin resistance and hyperglycemia: evidence for a combined transcriptional dysregulation of gluconeogenesis and fatty acid synthesis,” *Journal of Molecular Endocrinology*, vol. 32, no. 1, pp. 195–208, 2004.

[53] J.-P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” *European Cytokine Network*, vol. 17, no. 1, pp. 4–12, 2006.

[54] S. De Ferranti and D. Mozaffarian, “The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences,” *Clinical Chemistry*, vol. 54, no. 6, pp. 945–955, 2008.

[55] K. Meijer, M. de Vries, S. Al-Lahham et al., “Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages,” *PLoS One*, vol. 6, no. 3, 2011.

[56] A. G. Pockley, R. Wu, C. Lemne, R. Kiessling, U. De Faire, and J. Frostegård, “Circulating heat shock protein 60 is associated with early cardiovascular disease,” *Hypertension*, vol. 36, no. 2, pp. 303–307, 2000.
